For the Inventor, By the Inventor

Enter assignee name

London, United Kingdom

Cancer Research Campaign Technology Limited

USPTO Granted Patents = 62

CIPO Patents = 5

Forward Citations = 970

Loading Chart...

Loading Chart...

130 inventors (with patents filed for the assignee):

Caroline Joy Springer (15 out of 41 patents)

William Alexander Denny (6 out of 73 patents)

Michael Jarman (5 out of 16 patents)

4. Anthony Brian Mauger (5 out of 6 patents)

5. Robert I Dowell (5 out of 21 patents)

6. Philip John Burke (5 out of 6 patents)

7. Richard Marais (4 out of 26 patents)

8. Joseph Anthony Rafferty (4 out of 4 patents)

9. Amanda Jean Watson (4 out of 4 patents)

10. Richard Knox (4 out of 4 patents)

11. Thomas Connors (4 out of 4 patents)

12. Roger Sherwood (4 out of 4 patents)

13. Geoffrey Paul Margison (4 out of 4 patents)

14. Ronald Alfred Laskey (3 out of 10 patents)

15. Alan Ashworth (3 out of 15 patents)

Core Competencies:

Poly(ADP-Ribose) Polymerases

P53-MDM2 Interaction

Cyclin Dependent Kinase Inhibitors

Cell-Free Replication System

Papillomavirus L2 Protein

Anti-MCM5 Antibodies

Nitrogen Mustard Prodrugs

Prodrug Therapy

Nucleic Acid Amplification

Tumor Cell Treatment

Bacterial Nitroreductase

Chemical Compounds

62 patents: Sort by Forward Citations

1. 7429578 - Tricyclic inhibitors of poly(ADP-ribose) polymerases (2008-09-30),

2. 7083983 - Inhibitors of the interaction between P53 and MDM2 (2006-08-01),

3. 7018791 - Binding complexes (2006-03-28),

4. 6977298 - Tricyclic inhibitors of poly(ADP-ribose) polymerases (2005-12-20),

5. 6852755 - Nitrogen mustard compounds and prodrugs therefor (2005-02-08),

6. 6677345 - Cyclin dependent kinase inhibitors (2004-01-13),

7. 6531097 - Measuring the concentration of a substance (2003-03-11),

8. 6521405 - Cell-free replication system and uses thereof (2003-02-18),

9. 6492116 - Assay for identifying inhibitors of the interaction between proteins p53 and dm2 (2002-12-10),

10. 6380157 - Method of treatment using papillomavirus L2 protein (2002-04-30),

11. 6303618 - Cyclin dependent kinase inhibiting purine derivatives (2001-10-16),

12. 6303323 - Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies (2001-10-16),

13. 6255070 - Folding protein complexes (2001-07-03),

14. 6251933 - Seco precursors of cyclopropylindolines and their use as prodrugs (2001-06-26),

15. 6174532 - L2 immunogenic peptides of papillomavirus (2001-01-16),

Cancer Research Campaign Technology Limited (CRCTech) is a leading technology transfer company in the field of cancer research. Through partnerships and collaborations with researchers, clinicians, and industry stakeholders, CRCTech aims to accelerate the development and commercialization of innovative cancer technologies. With a focus on translating scientific discoveries into clinical applications, CRCTech plays a crucial role in bridging the gap between academia and industry to bring potential breakthroughs to patients and improve cancer outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

62 Patents

#54 in London

#287 in United Kingdom

#11,475 in the World

London, United Kingdom

Cancer Research Campaign Technology Limited

Forward Citations = 970

130 inventors:

Caroline Joy Springer (15 out of 41 patents)

William Alexander Denny (6 out of 73 patents)

Michael Jarman (5 out of 16 patents)

4. Anthony Brian Mauger (5 out of 6 patents)

5. Robert I Dowell (5 out of 21 patents)

Please report any incorrect information to support@idiyas.com

Loading…